These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26243735)

  • 101. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
    Bagel J; Nelson E; Keegan BR
    J Drugs Dermatol; 2017 Oct; 16(10):957-962. PubMed ID: 29036248
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs.
    Harrison C
    Nat Rev Drug Discov; 2013 May; 12(5):335. PubMed ID: 23629496
    [No Abstract]   [Full Text] [Related]  

  • 103. Chronic tearing induced by apremilast.
    Norris MR; Bielory L
    Ann Allergy Asthma Immunol; 2018 Sep; 121(3):375. PubMed ID: 29969663
    [No Abstract]   [Full Text] [Related]  

  • 104. Apremilast in psoriasis - a prospective real-world study.
    Vujic I; Herman R; Sanlorenzo M; Posch C; Monshi B; Rappersberger K; Richter L
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Apremilast is effective in controlling the progression of adult vitiligo: A case series.
    Majid I; Imran S; Batool S
    Dermatol Ther; 2019 Jul; 32(4):e12923. PubMed ID: 30977956
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience.
    Distel J; Cazzaniga S; Seyed Jafari SM; Emelianov V; Schlapbach C; Yawalkar N; Heidemeyer K
    Dermatology; 2022; 238(2):267-275. PubMed ID: 34091455
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
    Picchianti-Diamanti A; Spinelli FR; Rosado MM; Conti F; Laganà B
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807944
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review.
    Kahn JS; Casseres RG; Her MJ; Dumont N; Gottlieb AB; Rosmarin D
    J Drugs Dermatol; 2019 Apr; 18(4):. PubMed ID: 31013012
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study.
    Ferguson LD; Cathcart S; Rimmer D; Semple G; Brooksbank K; Paterson C; Brown R; Harvie J; Gao X; Radjenovic A; Welsh P; McInnes IB; Sattar N; Siebert S
    Rheumatology (Oxford); 2022 Mar; 61(3):1026-1034. PubMed ID: 34097014
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Effective treatment of nail psoriasis with apremilast: report of two cases and review of the literature.
    Magdaleno-Tapial J; Valenzuela-Oñate C; Ortiz-Salvador JM; Subiabre-Ferrer D; Hernández-Bel P
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677839
    [TBL] [Abstract][Full Text] [Related]  

  • 111. The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
    Artamonova OG; Karamova AE; Nikonorov AA; Verbenko DA; Vasileva EL; Kubanov AA
    Bull Exp Biol Med; 2021 May; 171(2):208-211. PubMed ID: 34173094
    [TBL] [Abstract][Full Text] [Related]  

  • 112. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
    Schafer PH; Chen P; Fang L; Wang A; Chopra R
    J Immunol Res; 2015; 2015():906349. PubMed ID: 25973439
    [TBL] [Abstract][Full Text] [Related]  

  • 113. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data.
    Kolli SS; Kepley AL; Cline A; Feldman SR
    Expert Opin Drug Saf; 2019 Jun; 18(6):523-536. PubMed ID: 31046481
    [TBL] [Abstract][Full Text] [Related]  

  • 114. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
    Wilsmann-Theis D; Kromer C; Gerdes S; Linker C; Magnolo N; Sabat R; Reich K; Mössner R
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2045-2050. PubMed ID: 34077577
    [TBL] [Abstract][Full Text] [Related]  

  • 115. COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast.
    Pacifico A; d'Arino A; Pigatto PDM; Malagoli P; Young Dermatologists Italian Network ; Damiani G
    Clin Exp Dermatol; 2021 Oct; 46(7):1344-1346. PubMed ID: 33969530
    [No Abstract]   [Full Text] [Related]  

  • 116. Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients.
    Ikumi K; Torii K; Sagawa Y; Kanayama Y; Nakada A; Nishihara H; Morita A
    J Dermatol; 2022 Apr; 49(4):e125-e126. PubMed ID: 34961971
    [No Abstract]   [Full Text] [Related]  

  • 117. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
    De Souza A; Strober BE; Merola JF; Oliver S; Franks AG
    J Drugs Dermatol; 2012 Oct; 11(10):1224-6. PubMed ID: 23134988
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
    Hoffmann M; Kumar G; Schafer P; Cedzik D; Capone L; Fong KL; Gu Z; Heller D; Feng H; Surapaneni S; Laskin O; Wu A
    Xenobiotica; 2011 Dec; 41(12):1063-75. PubMed ID: 21859393
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.
    Saraceno R; Bavetta M; Zangrilli A; Chiricozzi A; Potenza C; Chimenti S; Chimenti MS
    Expert Opin Biol Ther; 2013 Sep; 13(9):1325-34. PubMed ID: 23930916
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Emerging oral drugs for psoriasis.
    Mahmood T; Zaghi D; Menter A
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):209-20. PubMed ID: 25643592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.